before first-line treatment. Only testing for all 10 biomarkers delivers complete answers.
% OF PATIENTS TESTED
for every NSCLC patient. Incomplete testing can mean sub-optimal patient outcomes.
PATIENTS w/ TARGETABLE ALTERATIONS
Only the right testing drives the right treatment decisions
Test every newly diagnosed NSCLC patient for all 10 NCCN guideline biomarkers. Every time.
Wait for complete results to determine the most effective therapy.
Confidently choose the best possible first-line treatment - targeted therapy or immunotherapy +/- chemotherapy.
A thriving community of patient organizations advocate for complete testing before treatment.